Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

Core Insights - The peer-reviewed analysis indicates that icosapent ethyl (IPE) is associated with fewer total hospitalizations and reduced days lost due to hospitalization and death, highlighting its impact on patient-centered measures of disease burden [1][6]. Study Overview - The analysis involved 8,179 participants who were randomized to receive either IPE 2 g twice daily or a placebo, followed for a median of five years to assess the impact on hospitalization frequency and duration [2][4]. Key Findings - IPE treatment resulted in a 9% reduction in total hospitalizations (HR = 0.91, P = 0.017) and increased the likelihood of surviving without hospitalization (OR = 1.12, P = 0.016) [5]. - Participants treated with IPE experienced fewer days lost due to hospitalization or death, with a relative risk reduction of 7% (RR = 0.93, P < 0.001) [5]. Clinical Significance - The findings emphasize the real-world relevance of IPE for patients, potentially allowing them to maintain independence and spend more time at home, thus reducing the overall burden on healthcare systems [3][6]. - The results extend the benefits of IPE beyond cardiovascular prevention, indicating its role in improving quality of life for patients with heart disease or diabetes [3]. Background on IPE - IPE, marketed as VASCEPA/VAZKEPA, is the first prescription treatment approved by the FDA solely comprising icosapent ethyl, aimed at high-risk patients with persistent cardiovascular risk despite statin therapy [12][17]. - The REDUCE-IT study, which evaluated IPE, was a global cardiovascular outcomes study that included patients with controlled LDL-C levels and elevated triglycerides, demonstrating significant efficacy in reducing cardiovascular events [8][9]. Company Profile - Amarin Corporation is dedicated to reducing the cardiovascular disease burden and advancing cardiovascular care globally, with a commercialization model that includes direct sales in the U.S. and indirect distribution internationally [7].